News

Open Public Consultation on Strategic Research and Innovation Agenda for the upcoming European Partnership for Brain Health

Published on | 1 year ago

Programmes Health
Currently, an open consultation is ongoing on the Strategic Research and Innovation Agenda (SRIA) for the upcoming European Partnership for Brain Health.

To participate: follow this 
link until 14 August 2024.

This consultation invites the interested public and key stakeholders to contribute to the development of a comprehensive roadmap aimed at promoting and preserving brain health while reducing the burden of brain disorders across Europe. Further information is available on our website.

Background:The European Partnership on BrainHealth (EP BrainHealth)and its SRIA represent a collaborative effort to address the significant challenges posed by brain disorders, neurological and mental alike. Building on previous European initiatives such as the ERA-NET NEURON, JPND, the Human Brain Project, as well as the CSA EBRA. The current Coordination and Support Action (CSA) BrainHealth paves the way towards the EP BrainHealth. The EP BrainHealth will seek to preserve and promote brain health in society and to enhance the well-being of people with neurological and mental health 
conditions in Europe and worldwide.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1725 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.